Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology | Family Medicine
Disease Category: Depression (Major/Severe)
Location: United States, IL
Clinical Trial Details
Research Study Summary
A multicenter, randomized, double-blind, parallel group, placebo controlled, phase III, efficacy and safety study of 3 fixed dose groups of TC-5214 (S-mecamylamine) as an adjunct to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate resopnse to antidepressant therapy.
To evaluate if a compound called TC-5214 works better than placebo when added to current antidepressant therapy in patients who are experiencing an inadequate response to current therapy.
Please contact Alexian Brothers for more information on participation.
To Learn more
Both Male and Female
Date Last Changed:
July 22, 2013
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.